

News Release

FOR IMMEDIATE RELEASE

November 5, 2013

FOR MORE INFORMATION

Bruce Copeland

(913) 696-1601

bcopeland@vinceandassociates.com



Vince & Associates Clinical Research Completes Enrollment of Biosimilar Clinical Trial for Large Pharma Client

(Overland Park, KS, November 5, 2013) — [Vince & Associates Clinical Research](#), a premier provider of early phase clinical research services to the global biopharmaceutical industry, announces the completion of enrollment of a [biosimilar](#) clinical trial with nearly 150 subjects. This study compares a potential biosimilar product profile to the current approved US and EU innovator products, evaluating the pharmacokinetics, safety, tolerability and immunologic responses.

[Dr. Brad Vince](#), president and medical director of Vince & Associates, stated, “Development of a biosimilar relies on the ability to clearly demonstrate PK similarity in a single dose clinical trial. Enrolling healthy volunteers can be the most sensitive approach in order to detect PK differences between the test product and the innovator.”

“Our [Physician Research Model®](#) is especially important when conducting these types of clinical trials involving monoclonal antibodies. Our principal investigators are intricately involved in all aspects of clinical trials, ensuring that proper medical and technical procedures are completed to the highest degree of quality,” said Vince.

Lorraine M. Rusch, Ph.D., vice president shared that “Vince & Associates continues to provide new, innovative offerings in areas of early clinical development. The pharmacy facilities at VACR are ideally designed to support biosimilar studies as they are equipped with an ISO 8 rated ante room attached to an ISO 7 clean room containing a Class A2 Biological Safety Cabinet used for sterile compounding designed to support the evolving needs of our clients who are developing [large molecule](#), biosimilar pharmaceutical products.”

About Vince & Associates Clinical Research

[Vince & Associates Clinical Research](#) has provided clinical research services to the biopharmaceutical industry for more than a decade. The research professionals at Vince & Associates are proud to be recognized in the industry as a “Center of Research Excellence.”

Vince & Associates operates a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. Boutique-hotel-level amenities of the facility include 10 uniquely designed research suites. The 20-inch, bedside, touch-screen entertainment systems allow study volunteers individual access to watch TV and movies, surf the Internet or play a host of games. This new unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

-more -

About Altasciences

Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithmme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information

Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at <http://www.vinceandassociates.com/>.

#